Search results
Showing 16 to 30 of 63 results for hepatocellular carcinoma
Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)
Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.
View recommendations for IPG460Show all sections
Sections for IPG460
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Evidence-based recommendations on microwave ablation of hepatocellular carcinoma. This involves using heat from microwave energy to destroy the cancer cells.
View recommendations for IPG214Show all sections
Sections for IPG214
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
Transarterial Chemoembolisation for inoperable hepatocellular carcinoma
Register an interest in this interventional procedure ...
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Awaiting development [GID-TA10895] Expected publication date: TBC
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Awaiting development [GID-TA11116] Expected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Awaiting development [GID-TA11053] Expected publication date: TBC
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Awaiting development [GID-TA11076] Expected publication date: TBC
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.